BMTCTN-1904
Phase II
OPEN TO ACCRUAL
BMTCTN-1904 Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
IIT-TALANO-CART-ALL
Phase I
OPEN TO ACCRUAL
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3 and 4-1BB Signaling Domains in Patients with Relapsed and/or Refractory CD19 or CD20 B-Cell Acute Lymphoblastic Leukemia
PBMTC-ONC1401
Phase II
OPEN TO ACCRUAL
The Role of KIR-Favorably Mismatched Haploidentical Transplantation and KIR-Polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
PIDTC-CSIDE
Phase II
OPEN TO ACCRUAL *
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR alpha beta+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC CSIDE Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801
PTCTC-ONC1701-ENDRAD
Phase II
OPEN TO ACCRUAL
A Phase II Pilot Trial to Estimate Survival After a Non-Total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-Acute Lymphoblastic Leukemia (ALL) Who Are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Next-Generation-Sequence (NGS) Minimal Residual Disease (MRD) Negative